MMP-15 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-15 (UniProt P51511), expressed in HEK293 cells. Membrane-type matrix metalloproteinase used in ECM degradation assays, progelatinase A activation studies, and as an antibody validation standard.
Expression system
HEK293
Cat. #
REC-MMP15

In stock

SKU
REC-MMP15
$498.00

Target Overview

MMP-15 (Matrix metalloproteinase-15; UniProt P51511) is a 669-amino-acid membrane-anchored endopeptidase belonging to the MT-MMP (membrane-type matrix metalloproteinase) subfamily. It is classified under EC 3.4.24.- and is also commonly designated MT2-MMP or MT-MMP 2 in the literature. Unlike secreted MMPs, MMP-15 is expressed at the cell surface, where it participates in pericellular extracellular matrix (ECM) remodelling and has been reported to activate progelatinase A (MMP-2), placing it at an upstream regulatory node in the broader MMP proteolytic network. This recombinant form of human MMP-15 is produced in HEK293 mammalian cells, a system chosen to preserve the post-translational modifications — including glycosylation — that are characteristic of the native human protein and relevant to proper folding and catalytic activity. HEK293 expression is particularly appropriate for MT-MMPs, whose propeptide processing and activity are sensitive to the cellular glycosylation environment. Researchers use this reagent across several in vitro applications: as an active enzyme source for fluorogenic peptide-substrate cleavage assays, as a tool for profiling broad-spectrum or selective MMP inhibitors, and as a positive-control antigen for antibody validation by Western blot and ELISA. Investigators characterising MMP-15 substrate preferences — including gelatin, fibronectin, and other ECM components — will find this recombinant a practical source of defined, consistent enzyme activity. Researchers performing antibody validation work can pair this recombinant directly with the matched Triple Point Biologics antibody (SKU: RP-MMP15), which is validated for Western blot against human MMP-15.

Background

MMP-15 is a member of the matrix metalloproteinase family, a structurally related group of zinc-dependent endopeptidases collectively responsible for controlled proteolysis of extracellular matrix components including collagens, laminins, fibronectins, and proteoglycans. As a membrane-type MMP, MMP-15 is distinguished from secreted family members by its transmembrane domain, which tethers the enzyme to the plasma membrane and concentrates proteolytic activity at the cell surface. This localisation is mechanistically significant: surface-bound MT-MMPs can form complexes with TIMP-2 and pro-MMP-2 to facilitate activation of the latter, linking MMP-15 to gelatinase-mediated matrix turnover. In published research, MMP-15 transcript and protein expression have been characterised across a range of biological contexts relevant to tissue remodelling and disease. Babas et al. (2026) applied a machine learning approach to extracellular matrix protease transcript signatures — including MMP-15 — in the context of breast cancer survival prediction, illustrating the interest in MMP-15 as part of a multi-protease transcriptomic research panel (PMID: 42192859). Separately, MMP-15 has been identified among differentially expressed genes in transcriptomic analyses of diabetic retinopathy (PMID: 42228736), studied in the context of MMP-family dysregulation in alpha-1 antitrypsin deficiency (PMID: 41253406), and detected in tissue-derived extracellular vesicle proteomes in renal cell carcinoma research (PMID: 41656939). These published data collectively position MMP-15 as a research target of interest across fibrotic, oncological, and metabolic disease models. From a reagent standpoint, the recombinant protein serves as a defined enzymatic standard that is absent from the variable and often proteolytically complex milieu of cell lysates or conditioned media. This is particularly important for inhibitor dose-response experiments, where background MMP activity confounds IC50 measurements, and for substrate identification workflows where a single defined enzyme source is required. Researchers studying the MT-MMP axis — including MMP-14/MMP-15 redundancy in progelatinase activation — benefit from access to a consistent, well-characterised MMP-15 preparation. Triple Point Biologics has produced proteinase and inhibitor research reagents since 1994; this recombinant is manufactured and QC-tested under the same standards applied across the broader MMP reagent portfolio.

Applications

  • Fluorogenic peptide-substrate cleavage assay to measure MMP-15 endopeptidase activity
  • Inhibitor IC50 determination against small-molecule or biological MMP inhibitors
  • Progelatinase A (pro-MMP-2) activation assay to characterise MT-MMP activation cascades
  • Gelatin and fibronectin degradation assay to profile MMP-15 substrate specificity
  • Antibody validation positive control (Western blot and ELISA) — pairs with Triple Point Biologics RP-MMP15
  • Enzyme titration standard for quantitative ELISA-based detection of MMP-15 in biological samples
  • Substrate identification by mass spectrometry using recombinant MMP-15 as the defined protease source
  • Competitive binding and surface plasmon resonance studies of MMP-15 interactions with TIMPs or inhibitor scaffolds

References

  1. Babas R et al. Integrative Survival Prediction in Breast Cancer Using Extracellular Matrix Protease Transcript Signatures and Clinical Variables: A Machine Learning Approach. Cancers (Basel). 2026. doi:10.3390/cancers18101497. PMID: 42192859.
  2. Liang H et al. Transcriptome sequencing combined with experimental verification to explore potential key genes related to uric acid in diabetic retinopathy. PLoS One. 2026. doi:10.1371/journal.pone.0350132. PMID: 42228736.
  3. Wu X et al. Tissue-Derived Extracellular Vesicles Define Diagnostic Biomarkers for Renal Cell Carcinoma. J Extracell Vesicles. 2026. doi:10.1002/jev2.70221. PMID: 41656939.
  4. Lan X et al. Investigation of cellular senescence in the mouse liver caused by low dose fractionated X-ray therapy. Radiat Oncol. 2026. doi:10.1186/s13014-026-02837-6. PMID: 41965711.
  5. Tejwani V et al. Matrix metalloproteinases and disease severity among PI*MZ and PI*ZZ individuals in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort. BMJ Open Respir Res. 2025. doi:10.1136/bmjresp-2025-003585. PMID: 41253406.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for recombinant MMP-15 on SDS-PAGE or Western blot?

The full-length human MMP-15 protein (669 amino acids, UniProt P51511) has a predicted molecular weight of approximately 75 kDa. However, because this recombinant is produced in HEK293 mammalian cells, N-linked glycosylation adds mass, and the apparent MW on SDS-PAGE typically runs between 80–90 kDa under reducing conditions. If you are using this as a positive control with our matched rabbit polyclonal antibody RP-MMP15, expect a single prominent band in that 80–90 kDa range. Anomalous migration is common for MT-MMPs and does not indicate degradation.

What processing forms or isoforms of MMP-15 does this recombinant represent — propeptide, catalytic domain, or full-length?

REC-MMP15 is supplied as an active enzyme form in which the autoinhibitory propeptide has been removed, exposing the catalytic zinc-binding domain. It retains the hemopexin-like domain but lacks the transmembrane anchor, making it soluble in solution. This processed, soluble ectodomain closely mirrors the form generated by furin-mediated processing of native MT2-MMP at the cell surface. Researchers studying MMP-2 activation or ECM substrate cleavage in cell-free assays will find this the most relevant form, since the transmembrane anchor is not required for catalytic activity in vitro.

What substrates does MMP-15 cleave, and which fluorogenic substrate should I use for an activity assay?

MMP-15 is a broad-spectrum endopeptidase that cleaves ECM components including fibronectin, laminin, tenascin, and aggrecan. It also activates pro-MMP-2 by forming a complex with TIMP-2. For fluorogenic activity assays, the generic MMP substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (also called Knight substrate or FRET peptide I) is widely used and compatible with MMP-15. Excitation at 320 nm / emission at 405 nm. A typical starting concentration for REC-MMP15 is 10–50 nM enzyme in assay buffer, with substrate at 5–20 µM. Include 10 mM EDTA as a negative control to confirm zinc-dependent activity.

What assay buffer conditions are optimal for MMP-15 activity, and does the storage buffer interfere with fluorogenic assays?

REC-MMP15 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. For fluorogenic or FRET-based activity assays, a working assay buffer of 50 mM HEPES pH 7.0–7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35 is standard and well-tolerated by MT-MMPs. Dilute REC-MMP15 at least 1:10 into assay buffer before use to bring glycerol below 1%, which can otherwise quench fluorescence and inhibit enzyme kinetics. Do not add EDTA or EGTA to working dilutions — both chelate the active-site zinc and fully abolish activity.

What starting concentration of recombinant MMP-15 should I use for inhibitor IC50 assays?

For IC50 determinations, use REC-MMP15 at 5–20 nM final concentration, with fluorogenic substrate (e.g., Mca-PLGL-Dpa-AR-NH2) at a concentration near the Km (typically 10 µM for MMP family substrates). Enzyme concentration should be kept at least 10-fold below the lowest inhibitor concentration tested to avoid tight-binding artifacts (the Morrison equation applies if you cannot maintain this ratio). Pre-incubate enzyme with inhibitor for 30–60 minutes at 37°C before initiating the reaction with substrate. Include a broad-spectrum MMP inhibitor such as GM6001 (1 µM) as a positive inhibition control in each plate.

Can I use REC-MMP15 as a positive control for Western blot with the RP-MMP15 antibody?

Yes — this is one of the primary validated uses of REC-MMP15. The matched rabbit polyclonal antibody RP-MMP15 (/anti-mmp-15-rabbit-polyclonal-antibody) was raised and validated against the same recombinant protein, ensuring direct compatibility. For Western blot positive controls, load 50–100 ng of REC-MMP15 per lane alongside your cell lysate samples. Under reducing SDS-PAGE conditions, RP-MMP15 detects a band at 80–90 kDa. This pairing is particularly useful for confirming antibody lot-to-lot consistency and for validating new secondary antibody systems before committing precious tissue lysates.

How much recombinant MMP-15 should I load for a Western blot positive control lane?

50–100 ng per lane is the recommended starting range for REC-MMP15 when used as a Western blot positive control alongside the matched RP-MMP15 antibody. At this loading, a clean band at approximately 80–90 kDa is reliably detected without signal saturation at standard antibody dilutions (RP-MMP15 is typically used at 1:500–1:2000 in 5% BSA/TBST). If your cell lysate samples are relatively MMP-15-sparse — as is common in non-tumor lines — a 100 ng spike lane serves as an unambiguous reference to confirm antibody performance and transfer efficiency.

How should I handle, aliquot, and store REC-MMP15 to maintain activity over time?

REC-MMP15 is shipped on dry ice and should be stored at -20°C immediately upon receipt. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is formulated for long-term stability; purity is >95% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL. Prepare single-use aliquots before the first freeze to avoid repeated freeze-thaw cycles, which progressively reduce specific activity in metalloproteinases. Working dilutions should be prepared fresh in assay buffer on ice and used within 4 hours. Do not store diluted enzyme — glycerol is below the protective threshold once diluted.

Validation imagery coming soon

Western blot validation figures for REC-MMP15 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →